Implementing AI-Assisted, Patient-Friendly Imaging Report Summaries to Enhance Oncology Care Delivery
Sponsor: University of Wisconsin, Madison
Trial Details
| Condition | Oncology |
| Status | Recruiting |
| Participants | 2,000 |
| Est. Completion | 1 Jan 2027 |
| Last Updated | 30 Apr 2026 |
Primary Outcome
Proportion of Patient Participants who report the information presented in their results is "Somewhat easy to understand" or "Very easy to understand" when reviewed by themselves; Perceived impact of scan-result-related patient queries on Provider Participant workload
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria (Patient Participants): * Age 18 years or older * Having a current or prior cancer diagnosis (any cancer type) * Has active access to the UW Health MyChart patient portal. * Receiving care at UW Health within the Division of Hematology, Medical Oncology and Palliative Care or Department of Gynecologic Oncology. * Undergoing imaging studies (such as CT, MRI, or PET scans) as part of routine cancer care. * Willing and able to complete electronic REDCap surveys. * For interview participation: willing to participate in a 30-45-minute phone or video interview. Inclusion Criteria (Provider Participants): Cancer care providers will be eligible to participate in this study if they meet all of the following criteria: * Faculty physician (MD or DO) practicing in the Division of Hematology, Medical Oncology and Palliative Care or Department of Gynecologic Oncology at UW Health. * Involved in reviewing, discussing, or sharing imaging results with patients. * Planned to gain access to the AI-assisted, patient-friendly imaging summary tool as part of clinical implementation. * Willing and able to complete electronic surveys or participate in a brief interview (\~30 minutes). Exclusion Criteria (Patients): * Are unable to provide informed consent due to cognitive impairment or other limitations, as determined by the clinical or study team. * Enrolled in an active interventional clinical trial. Patients on biospecimen, registry, or non-interventional studies are eligible. * For the Patient Interview group only: Patients with radiographic disease progression will be excluded.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service